Canaccord Genuity analyst Jason Mills reiterated a Buy rating on Neovasc Inc (NVCN) today and set a price target of $1.10. The company’s shares opened today at $0.62, close to its 52-week low of $0.43.
According to TipRanks.com, Mills is a top 25 analyst with an average return of 23.4% and a 66.7% success rate. Mills covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Merit Medical Systems, and Edwards Lifesciences.
Currently, the analyst consensus on Neovasc Inc is a Hold with an average price target of $3.
See today’s analyst top recommended stocks >>
Based on Neovasc Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $13.26 million. In comparison, last year the company had a GAAP net loss of $5.03 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neovasc, Inc. engages in the development, manufacture, and marketing of medical devices for the cardiovascular marketplace. Its products includes Neovast Tiara and Neovasc Reducer. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.
